{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.68","upperLimit":"65.12","value":"55.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"The CR30 rate was defined as the percentage of participants with a CR at 30 months from study treatment initiation (date of first intake of any study treatment component), as determined by the investigator according to the guidelines used at the site.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 months","title":"Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}